Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading
This is the first study to investigate sex-specific mediation of varenicline on reductions in pre-quit smoking. Further investigation into varenicline-induced changes in smoking reinforcement and craving is warranted, particularly in females. For example, experimentally manipulating these mediators may inform them as mechanisms for smoking reduction.
Authors
- Thomas H. Brandon (ORCID: https://orcid.org/0000-0003-1559-5679)
- Eugene Maguin (ORCID: https://orcid.org/0000-0001-8617-6389)
- Craig R. Colder (ORCID: https://orcid.org/0000-0002-6863-673X)
- Robert K. Cooper (ORCID: https://orcid.org/0000-0003-4787-5501)
- Stephen T. Tiffany (ORCID: https://orcid.org/0000-0002-0735-1968)
- Kyler S. Knapp (ORCID: https://orcid.org/0000-0003-4737-4133)
- Samantha Johnstone (ORCID: https://orcid.org/0000-0002-5459-265X)
- Larry W. Hawk (ORCID: https://orcid.org/0000-0001-6593-9746)
- Sarah Tonkin (ORCID: https://orcid.org/0000-0001-5638-4363)
- Rebecca L. Ashare (ORCID: https://orcid.org/0000-0003-4664-009X)
- Martin C. Mahoney (ORCID: https://orcid.org/0000-0002-5069-1140)
- Jennifer M. Wray
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Moffitt Cancer Center (US)
- Ralph H. Johnson VA Medical Center (US)
- University of Oklahoma Health Sciences Center (US)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- Nicotine & Tobacco Research
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1093/ntr/ntaf100
- Citations
- 1
- Primary Topic
- Smoking Behavior and Cessation
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Pfizer
- University of Rochester
- National Institutes of Health
- University at Buffalo
- National Cancer Institute
- National Center for Advancing Translational Sciences